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To enable rationale vaccine design, studies of molecular and cellular mechanisms of immune recognition need to be linked with
clinical studies in humans. A major challenge in conducting such translational research studies lies in the management and
integration of large amounts and various types of data collected from multiple sources. For this purpose, we have established
“IMMUNOCAT”, an interactive data management system for the epitope discovery research projects conducted by our group. The
systemprovidesfunctions tostore,query, and analyze clinical and experimental data, enabling eﬃcient, systematic,andintegrative
data management. We demonstrate how IMMUNOCAT is utilized in a large-scale research contract that aims to identify epitopes
in common allergens recognized by T cells from human donors, in order to facilitate the rational design of allergy vaccines. At
clinical sites, demographic information and disease history of each enrolled donor are captured, followed by results of an allergen
skin test and blood draw. At the laboratory site, T cells derived from blood samples are tested for reactivity against a panel of
peptides derived from common human allergens. IMMUNOCAT stores results from these T cell assays along with MHC:peptide
binding data, results from RAST tests for antibody titers in donor serum, and the respective donor HLA typing results. Through
this system, we are able to perform queries and integrated analyses of the various types of data. This provides a case study for
the use of bioinformatics and information management techniques to track and analyze data produced in a translational research
study aimed at epitope identiﬁcation.
1.Introduction
A crucial step for rational subunit vaccine design is the
selection of antigens to include. For vaccines against infec-
tiousagents,antigenscapableofinducingprotectiveimmune
responses are desired. Several strategies based on genomic
and proteomic approaches are being used to identify subsets
of antigens that are highly expressed in general [1], on the
surface [2], or during infection [3]. Antigens from these
priority subsets are then followed up individually to test for
their capacity to induce protective immunity. An alternative
strategy that identiﬁes protective antigens directly is to map
targetsofimmuneresponsesinpreviouslyinfectedhoststhat
successfully cleared the infection. This strategy is applicable
whenever past infectious are known to provide protective
immunity. In those cases, the capacity of antigens to induce
protective immunity in a vaccine setting has been shown to
correlate with the magnitude of the response against that
antigen post infection [4]. Therefore, knowledge of targets
of immune responses in infected hosts has high value for
vaccine design against infectious diseases. Knowing immune
response targets is also crucial for the development of allergy
vaccines, whose goal is to modulate the pathologic immune
responses of allergic individuals towards those found in
non-allergics [5, 6] .S i m i l a r l y ,f o rc a n c e rv a c c i n e st ob e
successful, it is necessary to identify antigens targeted by
immune responses associated with tumor regression [7, 8].
In summary, identifying the targets and characteristics of
immune responses in well characterized host populations
enables the rational design of vaccines.
One established approach for the identiﬁcation and
characterization of T cell immune response is the use of pep-
tide based epitope mapping strategies. These are especially
eﬃcient when used in combination with bioinformatics
predictions of candidate peptides [9]. The identiﬁcation of
epitopes, the exact molecular unit of recognition within an2 Journal of Biomedicine and Biotechnology
antigen, also provides a mechanistic understanding of cross-
reactivity of immune responses for diﬀerent pathogens. This
has recently been applied to study T cell immunity to
swine ﬂu [10, 11], and is important when designing cross-
protective vaccines.
We have participated in two recently completed large-
scale T cell epitope mapping projects, one to characterize
epitopes responsible for the protective immunity conveyed
by the smallpox vaccine [12–15], another to characterize
epitopes in Arenaviruses [16–18], which has led to the
generation of a candidate for a cross protective vaccine
(M. Kotturi et al., PLoS Pathogens, in press). One lesson
learned from these studies is that their data management
is challenging, as the epitope response patterns discovered
are typically complicated [19]. Also, these studies require
the integration of large amounts and various types of
data collected from multiple clinical and laboratory sites.
Like many other groups, we have managed these data in
a collection of spreadsheets, lab notebooks, and database
systems designed for a single type of experiment. While
each of these provides a suﬃcient mechanism to capture a
speciﬁc type of information, the integrated analysis of these
data often becomes labor intensive. Worse, problems due
to inconsistencies in nomenclature and incompleteness of
datasets are often only discovered at the time of analysis
rather than at the time of data entry, which can make it hard
or impossible to rectify them.
One way to address these issues is to collect data, from
thestart,inanintegrateddatabasesystemwhichimmediately
connects data from diﬀerent sources. While this requires
more work upon data entry, compared to less formal means
of data capture such as spreadsheets, it greatly reduces the
eﬀort for data analysis. A deciding factor for our group to
move toward an integrated database system was the award
of a large scale NIH contract that aims to identify T cell
epitopes from common allergens with the ultimate goal to
facilitate the development of improved allergy vaccines. This
study involves tracking donors enrolled at two clinical sites,
capturing complex clinical history information, and storing
results from multiple experiments performed in-house and
through external providers (see Figure 1 for a breakdown
of the overall study). Our experience with previous studies
whichwerelesscomplex,suggestedthatthemaintenanceand
analysis of these data would be challenging. We therefore
decided to establish IMMUNOCAT, which aims to store all
data relevant for an integrated analysis of epitope mapping
experiments, with the ultimate goal to enable rational
vaccine design.
IMMUNOCAT integrates and enhances existing infor-
mation management systems in our laboratory. Two stand-
alone web-based relational databases were previously devel-
oped. ELICAT stores and analyzes results from ELISPOT
[20] experiments used to test T cells for their cytokine
secretion proﬁle in response to peptide antigens. TOPCAT
was designed to store the binding aﬃnities determined in
competitive peptide:MHC binding assays [21] utilizing a
TopCount instrument. The databases are linked by the use
of common peptide identiﬁers, which are assigned to every
peptide that is synthesized in our studies. For the allergen
epitope mapping study, we needed to link the results of T
cell reactivities stored in ELICAT with information about
the donor from whom the T cells were derived. We ﬁrst
built a new web-based database called DONORDB to store
answers from a clinical questionnaire, skin test results, and
records of blood samples. Subsequently, this donor database
was integrated with the existing ELICAT and TOPCAT
databases (Figure 2) through the use of shared MHC allele
and donation identiﬁers. The result is IMMUNOCAT, an
integration of three web-based databases.
In the following, we describe the features and compo-
nents of IMMUNOCAT, which has been in stable use in
our laboratory for over a year. With this system, we are able
to manage all data relevant to our epitope mapping studies
in a central location and ensure their quality and integrity.
Answers to integrated queries that would previously have
taken signiﬁcant eﬀort can now be determined instantly,
such as how many blood samples are available from donors
that showed T cell reactivity to a certain peptide. In
additiontotheallergyepitopemappingstudydescribedhere,
IMMUNOCAT has been modiﬁed for use in two recently
initiated epitope mapping studies for Dengue Virus and
MycobacteriumTuberculosis. This demonstrates the beneﬁts
of applying bioinformatics and information management
techniques to epitope mapping studies in order to facilitate
rational vaccine development.
2. User Administration
IMMUNOCAT provides diﬀerent functionality to diﬀerent
groups of users. Each user has an individual account created
by a database administrator. In order to access the database
throughtheweb,usershavetoidentifythemselvesbysupply-
ing a user name and password. Diﬀerent functionalities are
provided based on the user group assignments. For example,
there are two primary groups of users for DONORDB. The
ﬁrst group represents staﬀ members at the clinical sites, who
enter information from the clinical questionnaire and results
from the skin test and blood draw. The second group is
staﬀ members at the laboratory site, who track the use of
blood samples for each donor. Diﬀerent users within each
group are assigned diﬀerent levels of access. For example, lab
scientist supervisors have the ability to audit, add, delete, or
modify the information in the system as necessary. Other
lab scientists can only enter raw data and must request
lab scientist supervisors to correct, for example, data entry
errors. Separate projects using the DONORDB, such as the
epitope mapping studies for Dengue Virus, use diﬀerent web
addresses for user access.
3. System Components and Features
3.1. DONORDB at Clinical Site. DONORDB is used at
the clinical sites to capture information as donors are
enrolled, interviewed, and undergo clinical procedures. For
our ongoing allergen epitope mapping study, demographic
informationofthedonor,suchasgender,birthdate,ethnicity
and parents’ birthplaces (as an additional way to identifyJournal of Biomedicine and Biotechnology 3
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Figure 1: The allergy epitope mapping research workﬂow. In this study, allergic and normal donors were enrolled at two clinical sites
(University of California, San Diego and National Jewish Medical Research Center). During the clinical interview, donor demographic
information and medical history were recorded. Following that, allergen skin tests, hemoglobin test, and blood sample collection were
performed. All the data and blood samples were sent to LIAI for further experiments and analyses. At LIAI, blood samples were tested for
their immunogenicity (T cell activities) against a selected panel of peptides derived from common human allergens by ELISPOT assays
[20] (T cell assays). Concurrently, the selected peptides were tested for their binding capacities to a set of common MHC molecules [21].
Peptide binding to MHC molecules is a necessary, but not suﬃcient, requirement for T cell recognitions [22]. Blood samples were also
sent to an external company for radioallergosorbent (RAST) and human leukocyte antigens (HLA) typing test. The RAST test detects the
amount of the IgE antibody in the blood that reacts with a speciﬁc allergen [23]. HLA typing determines the speciﬁc HLA types expressed
by the donor, which is an indication of MHC restriction [24, 25]. The ﬁgure of skin test was adapted from the Wikimedia Commons ﬁle
“File:Allergy skin testing.jpg”. The ﬁgure of HLA typing was adapted from the Wikimedia Commons ﬁle “File:HLA.jpg”.
ethnicity), is ﬁrst entered. Next, a questionnaire is completed
based on donor interviews (Figure 3). The questionnaire
is tied to a scoring scheme that is used to classify donors
into diﬀerent disease categories, namely, three classiﬁcations
of “allergic rhinitis” (none, possible, and probable) and
“allergic asthma”. In terms of clinical procedures, the results
of a prick skin test for allergic reactions against 32 common
allergens are recorded in terms of ﬂare and wheal diameters.
Also, the hemoglobin count of a donor is measured and
recorded to determine if he/she is safely capable of donating
blood. If so, a separate blood donation visit is scheduled, and
thevolumeofblood drawnis recordedinthedatabasebefore
samplesareshippedforfurtheranalysistothelaboratorysite.
At every step, the system ensures that donors meet all
enrollment criteria, by notifying clinical staﬀ if a donor
falls under one of the exclusion criteria based on the
entered information. During initial enrollment, exclusion
would occur if, for example, the patient states that he
is currently receiving allergen immunotherapy without yet
being in maintenance. After initial enrollment, exclusion
would occur, for example, when the hemoglobin count is
too low to allow a blood draw, or when the donor is still
taking antihistamine medication right before the skin test.
Integrating these questions and criteria into the database
makes it easier for the clinical sites to keep track of all aspects
oftheenrollmentcriteria,andpromotesconsistencybetween
sites.
Only anonymized information about the donors is
entered at the clinical sites. As donors are enrolled, they get
assigned a donation identiﬁer by the system. This identiﬁer
is used to match blood samples shipped to the laboratory site
with the information collected at the clinical sites. The clini-
cal sites store the donation identiﬁers in their general patient
records, which allow them to, for example, match repeat
donations of a patient pre- and post immunotherapy, or
match existing patient identiﬁers established at the individ-
ual sites to the DONORDB donation identiﬁes. No person-
allyidentiﬁableinformation(suchasnamesorsocialsecurity
numbers) is stored in the database, which ensures that all
anonymization requirements for data analysis are met.4 Journal of Biomedicine and Biotechnology
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Figure 2: The architecture of IMMUNOCAT system. IMMUNOCAT is an integration of three web accessible relational databases.
DONORDB is designed for data collected during donor enrollment and clinical tests. ELICAT stores the data from T cell assays performed
using donor blood samples stimulated with a set of allergen derived peptides. TOPCAT stores the MHC-peptide binding data of the same set
of peptides. Simpliﬁed database structures are presented at the top of the ﬁgure. Arrows represent the links between database tables. Tables
shared by two databases are colored yellow. In DONORDB, donor information table is linked to skin test, disease state, and MHC allele
tables. In ELICAT, table of experimental spot forming cell (SFC) is linked to peptide, T cell source, and MHC allele tables. In TOPCAT, table
of experimental IC50 is linked to peptide and MHC allele tables. DONORDB is connected with ELICAT using donor IDs and MHC allele
IDs. ELICAT and TOPCAT are connected with each other using shared peptide IDs.
By default, the data entry process follows the order in
which the study was envisioned to be conducted. However,
this order can be speciﬁcally overruled by users. At any time
point, users can save completed data entry forms, and log
out.Theycanlogbackin,identifythedonortheywerework-
ing on based on the donation ID, and continue data entry.
If necessary, users can jump to diﬀerent entry parts at their
convenience. This was identiﬁed as critical functionality, as
in clinical practice the idealized workﬂow outlined above
is often interrupted due to changes in patients’ schedules,
and availability of time for data entry. Similarly, data entry
requires internet access which for various reasons may not
always be available. We found that enrollment information
at clinical sites is therefore often recorded on paper before
transferred into the database.
3.2. DONORDB at Laboratory Site. The lab scientists receive
blood samples from the clinical sites, and process them to
extract peripheral blood mononuclear cells (PBMCs). They
use the database to track the availability of PBMCs from each
donation, determine the number of vials that could initially
be made from the blood shipment, record the use of vials
in subsequent experiments, and track the location of the
remaining vials in the freezer.
For each donor, data from two experiments performed
at outside commercial laboratories are stored directly in
DONORDB. The ﬁrst set of data consists of IgE antibody
titers against a panel of allergens determined in a RAST
assay. The second set of data consists of the results from
HLA typing assays, which determine the speciﬁc set of MHC
molecules the donor expresses.
Simple queries can be run against DONORDB in a web-
based form (Figure 4). At this point, the system provides
query functions to retrieve results from skin tests and the
receipt of blood samples, as well as to monitor the number
of donors in the two clinical sites. For example, lab scientists
can query the database and see whether the blood samples
of speciﬁc donors have been received at LIAI. They can
also identify the donors who were skin test positive for a
particular allergen and recruited at a speciﬁc clinical site.
These queries are used routinely by laboratory scientists to
select suitable blood samples for experiments.
3.3. ELICAT Database. ELICAT was designed for the man-
agement of data from ELISPOT assays. In these assays
[13, 18], T cells are stimulated with peptide antigens, and
those that respond by producing cytokines are visualized
as individual spots. These recognized peptides are potential
candidates for inclusion in an allergy vaccine. The experi-
ments are performed on 96-well plates, and the numbers of
spots are counted by an automated ELISPOT reader. The raw
data generated is exported to a text ﬁle containing a matrix
whose elements denote the number of spots detected in each
well. This raw data is automatically imported into ELICAT,
where it is connected with information about experimental
design previously entered through the interface shown in
Figure 5. An experiment is deﬁned as one or more ELISPOT
plates run with the same layout and cells from the same
source. The plate layout speciﬁes which wells are used toJournal of Biomedicine and Biotechnology 5
Figure 3: DONORDB: demographic information. The Figure displays a screen shot of the form used during initial enrollment of a donor.
Figure 4: DONORDB: search functionality. The Figure shows a screen shot of the results generated when querying for all enrolled donors.
hold the tested peptides and which wells are used to hold
the controls. The peptides used are speciﬁed in a separate ﬁle
containing peptide identiﬁers.
Based on these inputs, ELICAT calculates summary
metrics for the ELISPOT results for each peptide or peptide
pool. The fraction of spot forming cells per million is
calculated based on the number of spots detected in a well
and the number of eﬀector T cells added. Based on replicate
spot counts, a P value is calculated that evaluates if the
detected spots for a peptide are signiﬁcantly higher than
those detected in negative control wells that contained no
peptides. Finally, a stimulation index, which divides the
average spot count for a peptide by the average background
value, is calculated.6 Journal of Biomedicine and Biotechnology
Figure 5: ELICAT database: experimental design functionality. The ﬁgure shows two screens used to capture the experimental design of
an ELISPOT experiment. By specifying the donor from whom T cells used in the experiment were derived, the experiment becomes linked
to the information for that donor in DONORDB, and some ﬁelds such as the HLA alleles expressed by that donor become prepopulated.
ELICAT also allows the users to specify the type of cytokines and cells used in the experiments (not shown here).
In the allergen epitope mapping study, two sets of
ELISPOT experiments are performed to identify peptide
epitopes. First, pools of peptides are screened for reactivity
with PBMCs from allergic donors. Secondly, the positive
pools are deconvoluted to identify which peptides caused
the response. As a cutoﬀ for the positive response >100 spot
forming cells per million, P<. 05 and stimulation index >2
were used. The ELICAT user interface allows description of
eachassay,includingidentiﬁcationofeachindividualpeptide
tested or deﬁnition of each peptide component of speciﬁc
pools.
3.4. TOPCAT Database. TOPCAT was the ﬁrst database
established in the laboratory, and its design was largely
replicated in ELICAT. TOPCAT is used to store results
from assays that evaluate MHC:peptide binding aﬃnity,
a necessary, but not suﬃcient, requirement for T cell
recognition [21]. In our assays [26, 27], the ability of the
tested peptides at diﬀerent concentrations to completely
inhibit the binding of a radiolabeled high aﬃnity ligand is
determined.Theconcentrationofthetestedpeptideatwhich
the number of labeled ligands bound is reduced by 50% is
the IC50 value. Under the condition utilized, measured IC50
values approximate the Kd value of the binding interaction
[28]. The IC50 values are calculated based on radioactivity
detection in a 96-well plate measured by TOPCOUNT
NXT microscintillation reader. Information on the tested
peptides, MHC alleles, and corresponding MHC-peptide
binding aﬃnities are stored and analyzed in the database.
All peptides used at the laboratory site are assigned a
peptide identiﬁer in the TOPCAT database, and the tubes
containingthepeptidearelabeledaccordingly.Thisidentiﬁes
the sequence of the peptide and the protein and organism
from which the peptide was derived, as well as the purityJournal of Biomedicine and Biotechnology 7
of the synthesis. If the same peptide is synthesized multiple
times, a new identiﬁer is assigned to each unique synthesis.
The ELICAT database uses the same peptide identiﬁers, and
uses them to retrieve information about peptides from the
TOPCAT system.
For the allergen epitope mapping study, peptides derived
from protein sequences of common human allergens were
synthesized. Each is being tested for binding aﬃnity against
a panel of 23 human MHC class II alleles. Through the
integration of the three databases shown in Figure 2,i t
now becomes possible to directly link the allergic status
of a donor, the peptides derived from the corresponding
allergens, and their binding aﬃnity to the MHC alleles
present in the donor and the T cell reactivities detected
towards these peptides.
4. SystemDesign ProcessandImplementation
ELICAT and TOPCAT have been in routine use in the lab
for more than 5 years. Regarding DONORDB, requirements
were gathered in terms of what information needs to
be captured for the process of donor enrollment, donor
interviews, clinical procedures, blood sample shipments,
and lab tests. For each step, the information desired to
track progress was identiﬁed. Based on this, prototype
web pages were created, and discussed with the clinical
collaborators and LIAI lab scientists. Test of these prototypes
was performed by both sites that analyzed use-scenarios,
which led to the identiﬁcation of additional requirements.
These were, primarily, giving the users more ﬂexibility in the
order in which data was entered, and the capacity to store
additional information. After three iterations, the prototypes
were considered complete, and a functional system was
implemented. The addition of more ﬁelds for new types of
studies will require going through the same design process
and modiﬁcations of the database and web application itself.
As we gather experience in the kinds of modiﬁcations to
expect, we plan to create tools that will ease making standard
extensions.
All three databases are relational databases with web-
browser-based interfaces and are implemented with SQL
server 2005. The user interface was implemented with
ASP for TOPCAT, and ASP.NET 2.0 for DONORDB and
ELICAT. All three databases are hosted on a Dual-Processor
Quad-Core Intel Xeon Rackmount Server. The database
information is stored on a RAID 5 drive which ensures
against single hard-disk failure, and is backed up daily
through the LIAI network.
5. Usage
At this point, clinical information for 86 donors at the
UCSD sites and 71 donors at NJMRC was deposited into
DONORDB. Immunogenicity and MHC binding data for
more than 60,000 peptides are stored in ELICAT and
TOPCAT. We have not, so far, encountered data loss during
operation. The source code of IMMUNOCAT is available for
download at http://donor.liai.org/Donor Source.zip.U s e r s
will need to have an installation of SQL Server 2005 DBMS
and ASP.NET 2.0 framework, and the ability to customize
and conﬁgure the database for their own purposes. The
code will be maintained for at least the next four years, and
updates will be made available as new versions of the systems
are completed. Prospective users are highly encouraged to
contact the authors with any installation problems. For
studies that require extensive modiﬁcations of the code and
for laboratories operating incompatible IT environments, it
will be preferable to redesign the application from scratch.
In those cases, the present manuscript should still be useful
in identifying requirements and reusing appropriate design
patterns.
6.FutureProspects
We are planning to implement more search and analysis
interfaces that take advantage of the integrated data in
IMMUNOCAT. Currently, such analyses are being done by
manually running SQL queries, which cannot be expected of
laboratory technicians.
We are in the process of extending DONORDB to
handle donors from three additional epitope-mapping stud-
ies, one dealing with donors from Dengue fever endemic
regions, another dealing with donors that have tubercu-
losis, and a third with donors recently vaccinated against
smallpox. This will require modifying some of the infor-
mation captured for each donor, such as the serological
typing of patients for the type of dengue viruses they
have been exposed to. Other aspects, such as MHC typ-
ing and blood sample collection, will remain the same.
In the longer term, we are aiming to make the cus-
tomization of DONORDB for individual studies easier by
allowing the addition of ﬁelds from predeﬁned modules.
This could, for example, mean that diﬀerent lab tests
performed could be chosen from an ontology such as
the Ontology for Biomedical Investigations [29], and that
vaccine terms could be taken from the Vaccine Ontology
[30].
Finally, one of the goals of IMMUNOCAT is to submit
data from completed studies into the Immune Epitope
Database [31, 32]. Currently, both TOPCAT and ELICAT
have export mechanisms that provide XML formatted data
that can be imported into the IEDB. These mechanisms
need to be integrated and further updated to integrate the
data from DONORDB, and provide comprehensive export
functionality of an entire study.
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